Join our daily newsletter At The Bell to receive exclusive market insights
- Visioneering Technologies (VTI) has unveiled an enhanced contact lens at the American Academy of Optometry annual meeting in Boston
- NaturalVue are multifocal one-day contact lenses with a TripleTear lubrication system and ultra-tapered edge
- A recent clinical study with 53 patients returned positive results, with nine out of 10 wearers saying their eyes felt clean and comfortable
- The company says this new lens redefines comfort for its patients, with the new lens addressing discomfort issues while delivering unique optics for patients of all ages
- Visioneering Technologies is up 7.53 per cent, trading at $1
Visioneering Technologies (VTI) has unveiled an enhanced contact lens, NaturalVue, following clinical studies.
NaturalVue are multifocal one-day contact lenses with a TripleTear lubrication system and ultra-tapered edge, launched at the American Academy of Optometry annual meeting in Boston.
The lubrication system on the contact uses three comfort agents, including hyaluronic acid, that work together to hydrate and lubricate, lock in moisture, and maintain a clean surface to stabilise tears.
The company said this new lens redefines comfort for its patients, with the new lens addressing discomfort issues while delivering unique optics for patients of all ages.
A recent clinical study with 53 patients returned positive results, with nine out of 10 wearers saying their eyes felt clean and comfortable, while experiencing significantly better stereoacuity than leading lenses tested.
“Making our NaturalVue Multifocal even better with innovation like the TripleTear lubrication system is yet another example of how we are ‘redefining vision’ and demonstrates our commitment to responding to the needs of patients and practitioners,” CEO Dr Stephen Snowdy said.
In addition to the NaturalVue launch, VTI appointed Dr Kuang-mon (Ashley) Tuan as Chief Medical Officer.
Dr Tuan will be responsible for managing clinical research studies, including the NaturalVue trial for myopia progression control in children, helping identify and develop new products, and lead efforts to communicate findings.
“We are proud to have Dr. Tuan join our team and look forward to the many contributions she will make to our organization as we seek to broaden our profile both geographically and through new product reach,” Dr Snowdy concluded.
Visioneering Technologies was up 7.53 per cent, trading at $1 at 2:53 pm AEDT.
